thalidomide has been researched along with Argentaffinoma in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with temozolomide and thalidomide was associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% among carcinoid tumors)." | 9.12 | Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006) |
| "Treatment with temozolomide and thalidomide was associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% among carcinoid tumors)." | 5.12 | Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006) |
| "Thalidomide was fairly well tolerated in patients with metastatic carcinoid/islet cell tumors, but failed to reveal any objective responses." | 2.73 | Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. ( Campbell, J; Shah, MH; Varker, KA, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pregun, I | 1 |
| Bodoky, G | 1 |
| Rácz, K | 1 |
| Tulassay, Z | 1 |
| Kulke, MH | 1 |
| Stuart, K | 1 |
| Enzinger, PC | 1 |
| Ryan, DP | 1 |
| Clark, JW | 1 |
| Muzikansky, A | 1 |
| Vincitore, M | 1 |
| Michelini, A | 1 |
| Fuchs, CS | 1 |
| Varker, KA | 1 |
| Campbell, J | 1 |
| Shah, MH | 1 |
| Chen, KC | 1 |
| Chang, YL | 1 |
| Pan, CT | 1 |
| Lee, YC | 1 |
1 review available for thalidomide and Argentaffinoma
| Article | Year |
|---|---|
[Carcinoid tumors].
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Biomarkers, Tumor; Bronchial Neoplasms; Carcinoid Tumo | 2010 |
2 trials available for thalidomide and Argentaffinoma
| Article | Year |
|---|---|
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; An | 2006 |
Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors.
Topics: Adenoma, Islet Cell; Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoid Tumor; Chrom | 2008 |
1 other study available for thalidomide and Argentaffinoma
| Article | Year |
|---|---|
Esophageal atypical carcinoid tumor with tracheal invasion.
Topics: Administration, Oral; Aged; Carcinoid Tumor; Combined Modality Therapy; Diagnosis, Differential; Eso | 2007 |